Astrea Bioseparations Spotlight

Astrea Bioseparations is a high-growth chromatography solutions provider, dedicated to facilitating drug developers and manufacturers in delivering high-purity biopharmaceuticals and advanced therapeutics globally.

This strategic acquisition extends Biotage’s chromatography franchise into the burgeoning bioprocessing segment, broadening exposure to biologics and advanced therapeutic customers. Astrea Bioseparations has already made a positive impact on Biotage’s financial performance, with the sales of the Biologics & Advanced Therapeutics Product Area experiencing growth of 589% in 2023. This segment now accounts for 24% of Biotage revenue (2022: 4%).

Notably, Astrea Bioseparations enhances Biotage’s financial outlook through its compelling organic growth rate, attractive gross margins, and exposure to recurring revenues. The acquisition also brings a rich, near-term pipeline of innovative product launches.

Astrea Bioseparations’ product portfolio includes chromatography resins, adsorbents, and columns as well as pioneering nanofiberbased purification technologies for biomanufacturing. Serving 21 Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved manufacturing processes, Astrea Bioseparations’ impact is global, with more than 180 employees distributed across production, research and development and sales sites in the UK, Isle of Man, Boston (USA) and Singapore.

In 2023, Astrea Bioseparations continued to diversify its product portfolio by introducing novel solutions utilizing their disruptive nanofiber technology for exosome and plasmid DNA purification. Additionally, they launched an upscaled version of their lentivirus purification solution.

These launches showcase Astrea Bioseparations’ robust research and development capabilities in addressing the rapidly evolving cell and gene therapy market. The products also mark significant progress in their efforts to accelerate toward manufacturing scale. Astrea Bioseparations has also focused on improving their
operational efficiency and reach-through reinforcing its foothold in the Americas region. Astrea Bioseparations increased its customer fulfillment and warehousing capabilities with a new facility in Canton, Massachusetts.

This investment supports the escalating demand for Astrea’s chromatography solutions, fortifying the company’s supply capabilities in the North American market

This article is from Biotage Annual Report 2023 – you can read the whole report here.